αEGFR-EndoP125A, a fusion that targeted EGFR, was more effective than both EndoP125A and the parental anti-EGFR antibody cetuximab at inhibiting endothelial angiogenesis, triple-negative breast cancer (TNBC) vasculogenic mimicry, and breast cancer cell motility in vitro. This evidence concerns the gene EGFR and breast cancer.